Compare MBRX & JAGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MBRX | JAGX |
|---|---|---|
| Founded | 2015 | 2013 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.1M | 5.0M |
| IPO Year | 2016 | 2014 |
| Metric | MBRX | JAGX |
|---|---|---|
| Price | $2.23 | $0.41 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 1 |
| Target Price | ★ $61.00 | $60.00 |
| AVG Volume (30 Days) | 112.9K | ★ 392.2K |
| Earning Date | 03-19-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $11,689,000.00 |
| Revenue This Year | N/A | $22.41 |
| Revenue Next Year | N/A | $30.00 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ 19.75 |
| 52 Week Low | $0.25 | $0.31 |
| 52 Week High | $7.98 | $15.48 |
| Indicator | MBRX | JAGX |
|---|---|---|
| Relative Strength Index (RSI) | 42.18 | 40.45 |
| Support Level | $0.37 | N/A |
| Resistance Level | $5.15 | $0.69 |
| Average True Range (ATR) | 0.14 | 0.05 |
| MACD | 0.08 | 0.00 |
| Stochastic Oscillator | 45.45 | 39.50 |
Moleculin Biotech Inc is a clinical stage pharmaceutical company focused on the development of a broad portfolio of drug candidates for the treatment of resistant tumors and viruses. The company's Annamycin program is a next-generation anthracycline designed to avoid multidrug resistance mechanisms with little to no cardiotoxicity.
Jaguar Health Inc is a commercial-stage pharmaceuticals company focused on developing novel, plant-based, non-opioid, and sustainably derived prescription medicines for people and animals with GI distress, specifically chronic, debilitating diarrhea. Its product Mytesi is a novel, first-in-class anti-secretory agent which has a basic normalizing effect locally on the gut, and this mechanism of action has the potential to benefit multiple disorders. It has two reportable segments namely human health and animal health. The company generates the majority of its revenue from the Human Health segment.